Regulatory volatility, scientific‑grade context requirements, and entrenched legacy processes are creating a level of operational complexity in pharma that makes even high‑value AI initiatives difficult to move from concept to production. In this episode, Art Shectman, CEO at Elephant Ventures, examines with host Marilie Fouché how leaders can cut through that complexity by isolating a single, clearly defined workflow slice and rebuilding it for near‑term, dependable deployment rather than long‑range architectural perfection. The discussion highlights how removing outdated process assumptions, selecting an atomic workflow with organizational alignment, and aiming for a contained operational win enable pharma teams to build momentum and scale AI responsibly in highly regulated environments. Learn how consultants are winning business with evidence-based AI ROI and building long-term capabilities instead of chasing short-term gains. Download our free PDF report, "3 Keys to Thriving in the Coming Era of Automation," at emerj.com/cok1

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Transcript

Related